Beam Therapeutics Inc. (NASDAQ:BEAM Get Rating) has earned an average recommendation of Moderate Buy from the eleven research firms that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating on ...

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Guggenheim 2023 ...

Beam Therapeutics Inc. (NASDAQ:BEAM Get Rating) CFO Terry-Ann Burrell sold 47,195 shares of the companys stock in a transaction that occurred on Wednesday, January 18th. The stock was sold at an average price of $45.14, for a total value of $2,130,382.30. Following the transaction, the chief ...

Beam Therapeutics Inc. (NASDAQ:BEAM Get Rating) insider Giuseppe Ciaramella sold 51,015 shares of the firms stock in a transaction on Monday, December 12th. The shares were sold at an average price of $42.70, for a total value of $2,178,340.50. Following the completion of the sale, the insider now ...

Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and ExpositionCAMBRIDGE, Mass., Dec. 10, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base ...